Cantor Fitzgerald Downgrades Cognition Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has downgraded Cognition Therapeutics (NASDAQ:CGTX) from Overweight to Neutral.
July 30, 2024 | 9:51 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan downgraded Cognition Therapeutics from Overweight to Neutral, indicating a less optimistic outlook on the stock.
The downgrade from Overweight to Neutral by a reputable analyst suggests a less favorable view on the stock's short-term performance, likely leading to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100